Usage: ANORO ELLIPTA is indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD). It is not intended for the relief of acute bronchospasm or asthma treatment, and its safety and effectiveness in asthma have not been established.
Usage: ASCENIV is indicated for the treatment of primary humoral immunodeficiency (PI) in adults and adolescents (12-17 years), including conditions such as congenital agammaglobulinemia, common variable immunodeficiency, X-linked agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies.
Usage: AUVI-Q® is indicated for the emergency treatment of Type I allergic reactions, including anaphylaxis due to insect stings, food, medications, and other allergens. It is intended for immediate self-administration in individuals at risk for anaphylaxis and is not a substitute for medical care.
Usage: BIVIGAM is indicated for treating primary humoral immunodeficiency (PI) in adults and children aged 2 years and older. It addresses conditions such as common variable immunodeficiency, X-linked agammaglobulinemia, congenital agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies.
Usage: CINQAIR® is indicated as an add-on maintenance treatment for adults (18+) with severe asthma exhibiting an eosinophilic phenotype. It is not intended for other eosinophilic conditions or for acute bronchospasm relief or status asthmaticus.
Usage: COMPLERA® is indicated for treating HIV-1 in adults and children (≥35 kg) as initial therapy for those with no treatment history and HIV-1 RNA ≤100,000 copies/mL, or to replace a stable regimen in virologically suppressed patients. Limitations include risk of virologic failure in those with higher baseline HIV-1 RNA.
Usage: DELSTRIGO® is indicated for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg, either as a complete regimen for those with no prior antiretroviral treatment or to replace the current regimen in patients who are virologically suppressed with no history of treatment failure.